Tumor suppressors status in cancer cell line encyclopedia

Molecular Oncology

Volumn 7, Issue 4, 2013, Pages 791-798

  Sonkin, Dmitriy ^a   Hassan, Mehedi ^a   Murphy, Denis J ^a   Tatarinova, Tatiana V ^a,b  

^a UNIVERSITY OF GLAMORGAN   (United Kingdom)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cancer cell line; CCLE; DNA methylation; Epigenetics; Loss of function; Tumor suppressor

Indexed keywords

NUTLIN 3; PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CARCINOGENESIS; EMBRYO DEVELOPMENT; ENHANCER REGION; GENE EXPRESSION; HETEROZYGOSITY LOSS; HISTONE MODIFICATION; HUMAN; LOSS OF FUNCTION MUTATION; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; TUMOR SUPPRESSOR GENE; WILD TYPE; X CHROMOSOME;

CANCER CELL LINE; CCLE; DNA METHYLATION; EPIGENETICS; LOSS OF FUNCTION; TUMOR SUPPRESSOR;

CELL LINE, TUMOR; DNA COPY NUMBER VARIATIONS; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; HUMANS; LOSS OF HETEROZYGOSITY;

EID: 84880732965     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.04.001     Document Type: Article

References (26)

1. Bale S., Devisscher M., Van Criekinge W., Rehm H.L., Decouttere F., Nussbaum R., Dunnen J.T.D., Willems P. MutaDATABASE: a centralized and standardized DNA variation database. Nat. Biotechnol. 2011, 29:117-118.
2. Barretina J., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehár J., Kryukov G.V., Sonkin D., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607.
3. Breslin T., Krogh M., Peterson C., Troein C. Signal transduction pathway profiling of individual tumor samples. BMC Bioinform. 2005, 6:163.
4. Efeyan A., Ortega-Molina A., Velasco-Miguel S., Herranz D., Vassilev L.T., Serrano M. Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin. Cancer Res. 2007, 67:7350-7357.
5. Finn R.S., Dering J., Conklin D., Kalous O., Cohen D.J., Desai A.J., Ginther C., Atefi M., Chen I., Fowst C., et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines invitro. Breast Cancer Res. 2009, 11:R77.
6. Fodde R. The APC gene in colorectal cancer. Eur. J. Cancer 2002, 38:867-871.
7. Guo Z., Zhang T., Li X., Wang Q., Xu J., Yu H., Zhu J., Wang H., Wang C., Topol E.J., et al. Towards precise classification of cancers based on robust gene functional expression profiles. BMC Bioinform. 2005, 6:58.
8. Heard E., Clerc P., Avner P. X-chromosome inactivation in mammals. Annu. Rev. Genet. 1997, 31:571-610.
9. Hodges E., Xuan Z., Balija V., Kramer M., Molla M.N., Smith S.W., Middle C.M., Rodesch M.J., Albert T.J., Hannon G.J., et al. Genome-wide in situ exon capture for selective resequencing. Nat. Genet. 2007, 39:1522-1527.
10. Hollstein M., Hainaut P. Massively regulated genes: the example of TP53. J.Pathol. 2010, 220:164-173.
11. Hubbell E., Liu W.-M., Mei R. Robust estimators for expression analysis. Bioinformatics 2002, 18:1585-1592.
12. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3:415-428.
13. Jones R.G., Thompson C.B. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 2009, 23:537-548.
14. Kanehisa M., Goto S., Sato Y., Furumichi M., Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 2012, 40:D109-D114.
15. Knudson A.G. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. U S A 1971, 68:820-823.
16. Kubbutat M.H., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature 1997, 387:299-303.
17. Lee E., Chuang H.-Y., Kim J.-W., Ideker T., Lee D. Inferring pathway activity toward precise disease classification. PLoS Comput. Biol. 2008, 4:e1000217.
18. Liberzon A., Subramanian A., Pinchback R., Thorvaldsdóttir H., Tamayo P., Mesirov J.P. Molecular signatures database (MSigDB) 3.0. Bioinformatics 2011, 27:1739-1740.
19. MacConaill L.E., Campbell C.D., Kehoe S.M., Bass A.J., Hatton C., Niu L., Davis M., Yao K., Hanna M., Mondal C., et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS ONE 2009, 4:e7887.
20. Mortazavi A., Williams B.A., McCue K., Schaeffer L., Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Meth. 2008, 5:621-628.
21. Payne S.R., Kemp C.J. Tumor suppressor genetics. Carcinogenesis 2005, 26:2031-2045.
22. Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 2007, 28:622-629.
23. Ponder B.A. Cancer genetics. Nature 2001, 411:336-341.
24. Sherry S.T., Ward M.H., Kholodov M., Baker J., Phan L., Smigielski E.M., Sirotkin K. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001, 29:308-311.
25. Stanbridge E.J. Human tumor suppressor genes. Annu. Rev. Genet. 1990, 24:615-657.
26. Vassilev L.T. Invivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.